Current Advances in Management of Neuroendocrine Neoplasms
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 May 2026 | Viewed by 603
Special Issue Editors
2. Cancer Research UK Oxford Centre, University of Oxford, Oxford OX1 2JD, UK
Interests: neuroendocrine tumours; epidemiology; clinical prediction models; statistical and machine learning in healthcare
Special Issue Information
Dear Colleagues,
Neuroendocrine neoplasms (NENs) are relatively rare yet profoundly clinically challenging tumours. Despite progress over the past 10-15 years manifesting as the first randomised clinical trials, the increasing centralisation of care in centres of excellence, and impressive gains in best standards of imaging, there remains significant scope for advancing the management of people with NENs.
This Special Issue seeks to highlight these advances and their routes to improving clinical care. We welcome submissions of original research and cutting edge reviews on topics that summarise modern developments in topics including, but not limited to:
- Epidemiology of NETs (pre- and/or post-diagnosis);
- Advances in diagnostics;
- New concepts or evidence regarding treatment strategies;
- Novel biomarkers;
- Artificial intelligence/machine learning.
This Special Issue will not only anticipate but define the near-future state of the art for NEN.
Dr. Ashley Kieran Clift
Prof. Dr. Andrea Frilling
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine tumours
- epidemiology
- clinical prediction models
- machine learning
- personalised medicine
- novel biomarkers
- diagnostics
- treatment
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
